Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I
Hematology Disease Topics & Pathways:
Research, Translational Research, Diseases, Myeloid Malignancies, Biological Processes, Technology and Procedures, Pathogenesis, Omics technologies
Methods. EVs were isolated from platelet-poor plasma of PV (n=10) , ET (n=10) and MF (n=20) patients at diagnosis and sex/age-matched healthy donors (HD; n=30) by size-exclusion chromatography and characterized for the expression of EV-related markers (western blot), size and concentration (nanoparticle tracking analysis), morphology (transmission electron microscopy) and phenotype for a panel of 37 EV surface proteins including immune/inflammatory-, platelet-, cancer, and stemness-related markers (flow cytometry). Semi-quantitative lipidomic profiling of MPN/HD EVs was performed by liquid chromatography/mass spectrometry. Lemon-EVs were isolated from Citrus limon L. juice by differential ultracentrifugation. Through EV functional analysis, we investigated the pro/anti-inflammatory properties of PV, ET and HD EVs, with /without Lemon-EVs, via measuring the in vitro nitric oxide (NO) production (Griess Test) by mouse macrophages and the in vitro pro-fibrotic activity of MPN/HD EVs by measuring alpha-smooth muscle actin (αSMA) in human dermal fibroblasts assay.
Results. Surface protein profiling showed that PV-EVs had a significant enrichment of immune/inflammatory- (CD8, CD29), EV- (CD9, CD63, CD81) and platelet-associated markers (CD41a, CD42b, CD62P) compared to those from HD. Of note, the expression of CD9, CD41b and CD42a on the surface of PV-EVs positively correlated with platelet number. The expression of CD9, CD29, and CD63 was found elevated in ET-EVs. Also, MF-EVs displayed significant higher expression of immune/inflammatory-(CD86, CD20), stem cell/tumor-associated markers (CD133-1, CD24, CD146, ROR1) vs HD and significantly lower expression of CD326, an epithelial/tumor-associated marker. Focusing on lipid class analysis, we discovered that PV-EVs were significantly enriched in ether phospholipids (plasmenyl-linked phosphatidylcholine PC-P and ether-linked PC-O) in comparison to the HD. When comparing MF vs HD-EVs, MF-EVs exhibit significant enrichment in ether-linked PC, diacylglycerol, ceramide, and phosphatidylethanolamine. Interestingly, ether phospholipids take part of oxidative stress response. Conversely, no significant differences were observed in lipid class cargo between ET and HD-EVs. Functional bioassays indicated that PV- and ET-EVs induce a pro-inflammatory response by promoting in vitro NO production in murine macrophages. Notably, Lemon-EVs were able to reduce the pro-inflammatory activity of ET- or PV-derived EVs. Moreover, only MF-EVs were able to promote the fibrotic activity of fibroblasts by elevating the protein expressions of α-SMA.
Conclusion. The integrated analysis of protein/lipid cargo of MPN EVs reveals that circulating EVs are enriched of immune/inflammatory and platelet biomarkers with a potential diagnostic role in MPN liquid biopsy. We also, demonstrated that circulating EVs can promote the inflammatory environment of PV and ET. Lemon-EVs may counteract this effect. Furthermore, MF-EVs have the potential to promote fibrosis, resembling the bone marrow fibrotic pattern seen in patients. Our work highlights the potential therapeutic implications of modulating EV-mediated inflammatory pathways in PV/ET microenvironment and provides new insights into the pathophysiology of MPN.
Disclosures: Zinzani: SECURA BIO, ADC Therap, Sandoz: Membership on an entity's Board of Directors or advisory committees; MSD, EUSAPHARMA, NOVARTIS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CELLTRION, GILEAD, JANSSEN-CILAG, BMS, SERVIER, ASTRAZENECA, TAKEDA, ROCHE, KYOWA KIRIN, Incyte, Beigene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Palandri: CTI: Consultancy, Honoraria; Sobi: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Constellation-Morphosys: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Telios: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sierra Oncology: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria; AOP: Consultancy, Honoraria; Novartis: Consultancy, Honoraria.